Weekly Prothena Corporation plc (NASDAQ:PRTA) Ratings as of Apr 16, 2018

April 16, 2018 - By Carey Conley

Prothena Corporation plc (NASDAQ:PRTA) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.18. That’s change of 0.47, from 2017Q3’s 1.65. 29 investors sold all, 32 reduced holdings as Prothena Corporation plc ratio dived. 44 grew stakes while 28 funds acquired stakes. Funds hold 31.32 million shares thus 0.27% more from 2017Q3’s 31.24 million shares.
Aqr Cap Management Ltd Liability Corporation holds 0% in Prothena Corporation plc (NASDAQ:PRTA) or 38,450 shs. Fisher Asset Management Lc accumulated 27,485 shs or 0% of the stock. California-based Wells Fargo & Mn has invested 0% in Prothena Corporation plc (NASDAQ:PRTA). Deutsche Fincl Bank Ag holds 231,468 shs or 0.01% of its capital. 25,075 were accumulated by Susquehanna Grp Limited Liability Partnership. Moreover, Pinnacle Limited has 0.24% invested in Prothena Corporation plc (NASDAQ:PRTA) for 339,864 shs. Renaissance Tech Ltd Co accumulated 42,700 shs. Legal General Gru Public Ltd reported 16,787 shs. Westfield Capital Mngmt Com Limited Partnership reported 680,659 shs. Parametric Port Assoc Limited Liability Company holds 0% or 11,608 shs. Washington Commercial Bank, Washington-based fund reported 6 shs. Cornerstone Advsr has invested 0% in Prothena Corporation plc (NASDAQ:PRTA). Gam Ag holds 76,300 shs. Parallax Volatility Advisers L P holds 0% or 5,922 shs in its capital. 9 are owned by Stratos Wealth Ltd.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Coverage

In total 7 analysts cover Prothena Corp (NASDAQ:PRTA). “Buy” rating has 6, “Sell” are 0, while 1 are “Hold”. 86% are bullish. 11 are the (NASDAQ:PRTA)’s analyst reports since October 23, 2017 according to StockzIntelligence Inc. On Thursday, November 2 RBC Capital Markets maintained Prothena Corporation plc (NASDAQ:PRTA) with “Buy” rating. The stock rating was downgraded by Wedbush to “Neutral” on Monday, November 20. In Thursday, April 5 report Barclays Capital maintained the stock with “Overweight” rating. The company rating was maintained by Deutsche Bank on Monday, October 23. On Monday, December 4 the stock of Prothena Corporation plc (NASDAQ:PRTA) earned “Buy” rating by Oppenheimer. The company rating was maintained by Cantor Fitzgerald on Wednesday, November 8. On Wednesday, March 21 the stock of Prothena Corporation plc (NASDAQ:PRTA) has “Buy” rating given by Oppenheimer. On Tuesday, March 20 the company was maintained by Cantor Fitzgerald. On Thursday, February 15 the stock has “Buy” rating by Cantor Fitzgerald. On Wednesday, December 20 the stock has “Buy” rating by Cantor Fitzgerald. Listed here are Prothena Corporation plc (NASDAQ:PRTA) PTs and latest ratings.

05/04/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $70 New Target: $50 Maintain
21/03/2018 Broker: Oppenheimer Rating: Buy New Target: $70.0 Maintain
20/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $69.0 Maintain
15/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $65.0 Maintain
20/12/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $65.0 Maintain
04/12/2017 Broker: Oppenheimer Rating: Buy New Target: $70.0 Maintain
20/11/2017 Broker: Wedbush Old Rating: Outperform New Rating: Neutral Downgrade
15/11/2017 Broker: Nomura Rating: Buy New Target: $87.0
08/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $80.0 Maintain
02/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $87.0 Maintain

On during the last trading session the stock increased $0.315 or 0.83%, reaching $38.285.Prothena Corporation plc has volume of 10,520 shares. Since April 16, 2017 PRTA has declined 31.00% and is downtrending. PRTA underperformed the S&P 500 by 42.55%.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion.The firm is worth $1.48 billion. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development.Last it reported negative earnings. The firm has a license, development, and commercialization agreement with F.

Prothena Corporation plc (NASDAQ:PRTA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: